In this cost effective analysis, researchers compared traditional skin testing for latent TB to newer interferon-gamma release assays (FDA approved recently). These assays work by incubating a blood sample with tuberculous antigen, and measuring the release of interferon (only tuberculous sensitized individuals will release interferon). They found these assays to be more cost-effective for screening, given they can be given to all individuals (even BCG-vaccinated), only require 1 visit, and do not require any interpretation. These tests will likely supplant skin testing in the near future (abstract).
by Deepak Asudani, MD, MPH, FHM Whether it is the prompt and expeditious international collaboration to develop an Ebola vaccine, or tardy but promising development of the first anti parasitic malarial vaccine or the fascinating technology utilizing synthetic DNA for vaccine development against MERS, these developments promise to highlight significant strides in vaccine development for […]
Economists describe preferences in two ways: revealed and stated. Say, for example, I asked you to implement a penalty program for your team with the goal of decreasing the number of occasions members did not clean their hands after a patient encounter. Because you know bad hands equal bad outcomes, you’re apt to offer up […]
by Eric Howell, MD, SFHM “Tell me what you know about antibiotics.” That’s the discussion I start with hospitalized patients all the time, right after they ask me to prescribe antibiotics for their simple cough, or other viral-like illness. And, from their perspective, asking for antibiotics makes sense. After all, antibiotics have been the physician’s […]